Novartis’ $12 billion acquisition of Avidity Biosciences “remains absolutely on track,” CEO Vas Narasimhan said, after the company disclosed a $1.9 billion …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.